Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093-0719, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.56). 01/2012; 59(4):376-81. DOI: 10.1097/QAI.0b013e318247ec54
Source: PubMed


Tenofovir is a nucleotide HIV reverse transcriptase inhibitor whose chemical properties suggest that it may not penetrate into the central nervous system in therapeutic concentrations. The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF).
CNS HIV Antiretroviral Therapy Effects Research is a multicenter observational study to determine the effects of antiretroviral therapy on HIV-associated neurological disease. Single random plasma and CSF samples were drawn within an hour of each other from subjects taking tenofovir between October 2003 and March 2007. All samples were assayed by mass spectrometry with a detection limit of 0.9 ng/mL.
One hundred eighty-three participants (age 44 ± 8 years; 83 ± 32 kg; 33 females; CSF protein 44 ± 16 mg/dL) had plasma and CSF samples drawn 12.2 ± 6.9 and 11 ± 7.8 hours post dose, respectively. Median plasma and CSF tenofovir concentrations were 96 ng/mL [interquartile range (IQR) 47-153 ng/mL] and 5.5 ng/mL (IQR 2.7-11.3 ng/mL), respectively. Thirty-four of 231 plasma (14.7%) and 9 of 77 CSF samples (11.7%) were below detection. CSF to plasma concentration ratio from paired samples was 0.057 (IQR 0.03-0.1; n = 38). Median CSF to wild-type 50% inhibitory concentration ratio was 0.48 (IQR 0.24-0.98). Seventy-seven percent of CSF concentrations were below the tenofovir wild-type 50% inhibitory concentration. More subjects had detectable CSF HIV with lower (≤ 7 ng/mL) versus higher (>7 ng/mL) CSF tenofovir concentrations (29% versus 9%; P = 0.05).
Tenofovir concentrations in the CSF are only 5% of plasma concentrations, suggesting limited transfer into the CSF, and possibly active transport out of the CSF. CSF tenofovir concentrations may not effectively inhibit viral replication in the CSF.

Download full-text


Available from: Brookie M Best, Oct 10, 2015
1 Follower
52 Reads
  • Source
    • "Recent studies have indicated that anti-retroviral drugpenetration is site-and compound-specific, and drugs that penetrate poorly may allow virus replication at that site even when plasma viral load is below 50 copies ml 21 (Best et al., 2012; Di Mascio et al., 2009; Else et al., 2011; Halfon et al., 2010; Kwara et al., 2008; Launay et al., 2011). Since the rate of reactivation of latent viruses in resting T-cells is unknown in vivo (Siliciano & Siliciano, 2010), it is unclear whether it occurs frequently enough to maintain the low-level viraemia that is detected in patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4+ memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.
    Journal of General Virology 01/2013; 94(Pt 5). DOI:10.1099/vir.0.049296-0 · 3.18 Impact Factor
  • Source
    • "Cell types that contribute to HIV-1 persistence by formation of reservoirs include latently infected resting CD4+ T cells with integrated provirus, dendritic cells, macrophages, bone marrow haematopoietic stem cells and astrocytes [86-89]. Furthermore, persistence of HIV-1 is also promoted by the presence of the virus in so called viral sanctuaries – infection sites in the body which are difficult to reach by antiviral drugs and are additionally immune privileged niches [13,90]. Therefore, eradication of HIV-1 from these sites is hardly feasible [89]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophages are important target cells for the Human Immunodeficiency Virus Type I (HIV-1) in vivo. Several studies have assessed the molecular biology of the virus in this cell type, and a number of differences towards HIV-1 infection of CD4+ T cells have been described. There is a broad consensus that macrophages resist HIV-1 infection much better than CD4+ T cells. Among other reasons, this is due to the presence of the recently identified host cell restriction factor SamHD1, which is strongly expressed in cells of the myeloid lineage. Furthermore, macrophages produce and release relatively low amounts of infectious HIV-1 and are less sensitive to viral cytotoxicity in comparison to CD4+ T cells. Nevertheless, macrophages play a crucial role in the different phases of HIV-1 infection. In this review, we summarize and discuss the significance of macrophages for HIV-1 transmission, the acute and chronic phases of HIV-1 infection, the development of acquired immunodeficiency syndrome (AIDS) and HIV-associated diseases, including neurocognitive disorders. We propose that interaction of HIV-1 with macrophages is crucial during all stages of HIV-1 infection. Thus, long-term successful treatment of HIV-1 infected individuals requires potent strategies to prevent HIV-1 from entering and persisting in these cells.
    Retrovirology 10/2012; 9(1):82. DOI:10.1186/1742-4690-9-82 · 4.19 Impact Factor
  • Source
    • "As a result of efforts to treat as many HIV-infected individuals as possible, the requirement for medications for comorbid diseases, the challenge to conducting relevant clinical pharmacology research as quickly as possible is considerable [28]. Ongoing research in the areas of preexposure prevention with oral ART or vaginal or rectal microbicides, and " treatment as prevention " to reduce new HIV infections, along with nanomedicine strategies, pediatric cART dosing, pregnancy, and geriatric considerations also include therapeutic drug monitoring and novel clinical pharmacology components [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41]. "
    AIDS research and treatment 07/2012; 2012:973627. DOI:10.1155/2012/973627
Show more